REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2022 Conference

ROCKVILLE, Md., Feb. 4, 2022 /PRNewswire/ — Data for Cohort 1 with six months of follow-up from the Phase II ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy to be presented REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral presentations, including updated…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.